Germin8 Ventures

Germin8 Ventures is a Chicago-based multi-stage venture capital firm founded in 2017 by Michael Lavin, focused on transformative investments in agtech and food technology across the global value chain. The firm manages approximately $75 million across multiple funds, including Fund I ($20 million, closed 2019) and Fund II. Germin8 takes a high-conviction approach -- described internally as 'rifle shots, not shotgun shots' -- making initial investments of $1 million to $3 million with an average contribution exceeding $2 million per deal and reserving two-thirds of capital for follow-on rounds. The firm leads and co-invests in companies addressing what it identifies as a broken global food system. The portfolio of 19 investments spans consumer innovation, industrial agtech, food technology and alternative foods, frontier science, and computational tools for agriculture, food, and nutrition. Notable investments include Fieldin ($30 million Series B, precision agriculture), Enko Chem ($70 million Series C, crop protection chemistry), Brightseed Bio ($68 million Series B, plant bioactives and health), CropX (soil analytics), Bushel (grain marketing), AgriWebb (livestock management), Avalo (AI-powered plant breeding), Alpine Bio, Wheeler Bio, and Matterworks (healthcare technology, latest investment June 2025). The firm also monitors Israeli agtech innovation as part of its global deal flow strategy. Germin8's team comprises veterans from global food and agriculture companies, technology firms, and research institutions, supported by strategic advisors drawn from across the industry. Managing Partner Michael Lavin was interviewed by AgTech Navigator in March 2025 discussing venture capital's 'healthy correction' in the sector. The firm's focus on environmental sustainability, producer economics, and population health runs through every investment decision.